Who is sponsoring NCT00930046?

NCT00930046 is sponsored by Boston Children's Hospital.

What drugs are being tested in NCT00930046?

Interventions in NCT00930046: Ropivacaine wound catheter, Saline wound catheter.

What condition does NCT00930046 study?

NCT00930046 studies Obstruction of Pelviureteric Junction.

Is NCT00930046 still recruiting?

NCT00930046 is currently terminated. Last updated 28 April 2020.

Are results published for NCT00930046?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-04-28 · How we verify

NCT00930046

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine

Terminated NA Results posted Last updated 28 April 2020

What this trial tests

NA trial testing Ropivacaine wound catheter in Obstruction of Pelviureteric Junction in 15 participants. Terminated before completion.

Timeline

24 April 2009

Primary endpoint
6 September 2011

6 September 2011

Quick facts

Lead sponsor	Boston Children's Hospital
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	15
Start date	24 April 2009
Primary completion	6 September 2011
Estimated completion	6 September 2011
Sites	2 locations across United States

Drugs / interventions tested

Ropivacaine wound catheter
Saline wound catheter

Conditions studied

Obstruction of Pelviureteric Junction — all drugs for Obstruction of Pelviureteric Junction →

Sponsor

Boston Children's Hospital

Who can join

Adults 3 Months to 14, any sex, with Obstruction of Pelviureteric Junction. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Morphine Primary · 48 hours

Total amount of morphine used in the first 48hrs immediately after surgery

Group	Value	95% CI
Ropivacaine Group	2.2	± 1.8
Normal Saline Group	3.5	± 1.8

FLACC Pain Intensity [Faces Legs Activity Cry Consolability] 0-10 Points Secondary · 48 hours post-operatively

Observational FLACC pain intensity assessment tool that consists of observing the Faces Legs Activity Cry Consolability (FLACC) by the bedside nursing staff. This pain assessment tool is validated in non-verbal children and children at 7 years and younger. Minimum value is 0 and the maximum value is 10, where 0 represents no pain which is a better outcome.

Group	Value	95% CI
Ropivacaine Group	1.3	± 0.7
Normal Saline Group	1.9	± 1.8

Sponsor's own description

The investigators propose a prospective blinded randomized control trial (RCT) to assess the efficacy and safety of a simple method of continuous infusion of a local anesthetic, ropivacaine, via a surgical wound to control pain after ureteropelvic junction (UPJ) stenosis correction in children during the first 48 hrs after surgery. The investigators hypothesize that this technique will provide greater pain relief post-operatively and reduce the need for systemic opioid use along with a reduction in associated side effects of such analgesics.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Boston Children's Hospital trials

Trials by the same sponsor.

NCT06804382 — Academic Detailing to Optimize PrEP Implementation in Pediatric Primary Care Settings: ADOPT-PrEP · NA · not yet recruiting
NCT05113394 — Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy · Phase 2 · withdrawn
NCT06434220 — Effect of Predictive Model on ED Physician Assessments of Patient Disposition · NA · not yet recruiting
NCT07476430 — Readiness Outcomes Affecting Return to Sport 3.0 · NA · not yet recruiting
NCT06706336 — Radon Asthma Intervention Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00930046 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boston Children's Hospital
Last refreshed: 28 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00930046.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing